Status:
TERMINATED
Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Conditions:
Mild to Moderate COVID-19
Eligibility:
All Genders
19+ years
Phase:
PHASE2
PHASE3
Brief Summary
To evaluate the efficacy and safety after administration of DWJ1248 in patients with mild to moderate COVID-19 compared to the placebo.
Eligibility Criteria
Inclusion
- Adults over the age of 19 as of the signed date in written consent
- Subjects with mild or moderate COVID-19 according to RT-PCR test (Total score of NEWS is 0-6 or if one item is 3 points)
- Subjects who have symptoms within 7 days or 72 hours after diagnosis
Exclusion
- Subjects who cannot orally administer the investigational products
- Subjects who need administration of immunosuppressants
- Subjects who are allergic or sensitive to investigational products or its ingredients
- Subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening
- Subjects who have been identified with uncontrolled concomitant diseases or conditions, including significant mental illness and social conditions, that may affect compliance with clinical trial procedures according to the determination of the investigators
Key Trial Info
Start Date :
September 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 18 2022
Estimated Enrollment :
432 Patients enrolled
Trial Details
Trial ID
NCT04521296
Start Date
September 11 2020
End Date
March 18 2022
Last Update
June 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea